POXEL SA (POXEL.PA)

FR0012432516 - Common Stock

0.515  -0.01 (-0.96%)

Fundamental Rating

1

POXEL gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 74 industry peers in the Biotechnology industry. POXEL may be in some trouble as it scores bad on both profitability and health. POXEL is valied quite expensively at the moment, while it does show a decent growth rate.



0

1. Profitability

1.1 Basic Checks

POXEL had negative earnings in the past year.
In the past year POXEL has reported a negative cash flow from operations.
POXEL had negative earnings in 4 of the past 5 years.
In the past 5 years POXEL always reported negative operating cash flow.

1.2 Ratios

The Return On Assets of POXEL (-345.44%) is worse than 90.00% of its industry peers.
Industry RankSector Rank
ROA -345.44%
ROE N/A
ROIC N/A
ROA(3y)-60.88%
ROA(5y)-43.4%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

POXEL has a Gross Margin (0.13%) which is comparable to the rest of the industry.
The Profit Margin and Operating Margin are not available for POXEL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 0.13%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

0

2. Health

2.1 Basic Checks

POXEL does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for POXEL has been increased compared to 1 year ago.
The number of shares outstanding for POXEL has been increased compared to 5 years ago.
POXEL has a worse debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of -13.43, we must say that POXEL is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of POXEL (-13.43) is worse than 84.29% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -13.43
ROIC/WACCN/A
WACC7.24%

2.3 Liquidity

A Current Ratio of 0.77 indicates that POXEL may have some problems paying its short term obligations.
The Current ratio of POXEL (0.77) is worse than 85.71% of its industry peers.
POXEL has a Quick Ratio of 0.77. This is a bad value and indicates that POXEL is not financially healthy enough and could expect problems in meeting its short term obligations.
POXEL's Quick ratio of 0.77 is on the low side compared to the rest of the industry. POXEL is outperformed by 84.29% of its industry peers.
Industry RankSector Rank
Current Ratio 0.77
Quick Ratio 0.77

4

3. Growth

3.1 Past

The earnings per share for POXEL have decreased strongly by -42.62% in the last year.
The Revenue has grown by 650.49% in the past year. This is a very strong growth!
The Revenue for POXEL have been decreasing by -33.77% on average. This is quite bad
EPS 1Y (TTM)-42.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-78.52%
Revenue 1Y (TTM)650.49%
Revenue growth 3Y-70.61%
Revenue growth 5Y-33.77%
Sales Q2Q%509.64%

3.2 Future

Based on estimates for the next years, POXEL will show a decrease in Earnings Per Share. The EPS will decrease by -8.92% on average per year.
The Revenue is expected to grow by 86.16% on average over the next years. This is a very strong growth
EPS Next Y39.72%
EPS Next 2Y2.27%
EPS Next 3Y-1.77%
EPS Next 5Y-8.92%
Revenue Next Year-49.6%
Revenue Next 2Y322.98%
Revenue Next 3Y54.02%
Revenue Next 5Y86.16%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

0

4. Valuation

4.1 Price/Earnings Ratio

POXEL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for POXEL. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.27%
EPS Next 3Y-1.77%

0

5. Dividend

5.1 Amount

No dividends for POXEL!.
Industry RankSector Rank
Dividend Yield N/A

POXEL SA

EPA:POXEL (7/16/2024, 7:00:00 PM)

0.515

-0.01 (-0.96%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap25.14M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -345.44%
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM 0.13%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.12
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 0.77
Quick Ratio 0.77
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-42.62%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y39.72%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)650.49%
Revenue growth 3Y-70.61%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y